NYSE:RMD - ResMed Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$103.74 -3.20 (-2.99 %)
(As of 11/12/2018 04:00 PM ET)
Previous Close$106.94
Today's Range$103.36 - $107.00
52-Week Range$81.90 - $116.64
Volume625,158 shs
Average Volume697,995 shs
Market Capitalization$15.24 billion
P/E Ratio29.39
Dividend Yield1.36%
Beta0.97
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides humidifiers, carry bags, and breathing circuits; data communications and control products, such as AirView Diagnostics, EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules; U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; and myAir, a patient engagement application that provides sleep data and a daily score based on their previous night's data, as well as offers business management software and services to medical equipment and home health providers. It markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 120 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNYSE:RMD
Previous Symbol
CUSIP76115210
Phone858-836-5000

Debt

Debt-to-Equity Ratio0.27
Current Ratio2.58
Quick Ratio1.91

Price-To-Earnings

Trailing P/E Ratio29.39
Forward P/E Ratio28.04
P/E Growth2.73

Sales & Book Value

Annual Sales$2.34 billion
Price / Sales6.32
Cash Flow$4.2674 per share
Price / Cash24.31
Book Value$13.34 per share
Price / Book7.78

Profitability

EPS (Most Recent Fiscal Year)$3.53
Net Income$315.58 million
Net Margins13.94%
Return on Equity26.29%
Return on Assets15.99%

Miscellaneous

Employees5,940
Outstanding Shares142,500,000
Market Cap$15.24 billion
OptionableOptionable

ResMed (NYSE:RMD) Frequently Asked Questions

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed announced a quarterly dividend on Friday, October 26th. Investors of record on Thursday, November 8th will be given a dividend of $0.37 per share on Thursday, December 13th. This represents a $1.48 dividend on an annualized basis and a yield of 1.43%. The ex-dividend date of this dividend is Wednesday, November 7th. View ResMed's Dividend History.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) released its earnings results on Thursday, October, 25th. The medical equipment provider reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.80 by $0.01. The medical equipment provider earned $588.28 million during the quarter, compared to analysts' expectations of $576.66 million. ResMed had a net margin of 13.94% and a return on equity of 26.29%. View ResMed's Earnings History.

When is ResMed's next earnings date?

ResMed is scheduled to release their next quarterly earnings announcement on Monday, January 28th 2019. View Earnings Estimates for ResMed.

What price target have analysts set for RMD?

9 analysts have issued 12 month price objectives for ResMed's stock. Their predictions range from $109.00 to $109.00. On average, they anticipate ResMed's share price to reach $109.00 in the next twelve months. This suggests a possible upside of 5.1% from the stock's current price. View Analyst Price Targets for ResMed.

What is the consensus analysts' recommendation for ResMed?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 1 sell rating, 5 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ResMed.

Has ResMed been receiving favorable news coverage?

Press coverage about RMD stock has been trending negative on Monday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. ResMed earned a media sentiment score of -2.6 on InfoTrie's scale. They also assigned media headlines about the medical equipment provider a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an impact on the company's share price in the near future.

Who are some of ResMed's key competitors?

Who are ResMed's key executives?

ResMed's management team includes the folowing people:
  • Mr. Michael J. Farrell BE, SM, MBA, CEO & Director (Age 46)
  • Mr. Robert A. Douglas, Pres & COO (Age 58)
  • Mr. Brett A. Sandercock, Chief Financial Officer (Age 51)
  • Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Sec. (Age 59)
  • Mr. James Hollingshead, Pres of Sleep Bus. (Age 55)

Who are ResMed's major shareholders?

ResMed's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.85%), FMR LLC (5.52%), Bank of New York Mellon Corp (1.15%), JPMorgan Chase & Co. (0.94%), Congress Asset Management Co. MA (0.67%) and American Capital Management Inc. (0.45%). Company insiders that own ResMed stock include Brett Sandercock, Christopher G Roberts, David Pendarvis, Franz Kozich, Gary W Pace, James Hollingshead, John P Wareham, Jr Gregor K Emmert, Peter C Farrell, Richard Mchale, Richard Sulpizio, Ronald R Taylor and Warren Russell Hawkins. View Institutional Ownership Trends for ResMed.

Which major investors are selling ResMed stock?

RMD stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, First Trust Advisors LP, West Coast Financial LLC, Congress Asset Management Co. MA, Tandem Investment Advisors Inc., Swiss National Bank, Callahan Advisors LLC and Meag Munich Ergo Kapitalanlagegesellschaft MBH. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Richard Mchale, Richard Sulpizio and Ronald R Taylor. View Insider Buying and Selling for ResMed.

Which major investors are buying ResMed stock?

RMD stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Canada Pension Plan Investment Board, NN Investment Partners Holdings N.V., Denali Advisors LLC, Janus Henderson Group PLC, Wells Fargo & Company MN, RPG Investment Advisory LLC and Robeco Institutional Asset Management B.V.. Company insiders that have bought ResMed stock in the last two years include Franz Kozich, Jr Gregor K Emmert and Warren Russell Hawkins. View Insider Buying and Selling for ResMed.

How do I buy shares of ResMed?

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $103.74.

How big of a company is ResMed?

ResMed has a market capitalization of $15.24 billion and generates $2.34 billion in revenue each year. The medical equipment provider earns $315.58 million in net income (profit) each year or $3.53 on an earnings per share basis. ResMed employs 5,940 workers across the globe.

What is ResMed's official website?

The official website for ResMed is http://www.resmed.com.

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]


MarketBeat Community Rating for ResMed (NYSE RMD)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  257 (Vote Outperform)
Underperform Votes:  526 (Vote Underperform)
Total Votes:  783
MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote "Outperform" if you believe RMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/12/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel